IL94021A - A non-typical neuroleptic preparation that includes 5-chloro-1-) 4-fluorophenyl (-3-) 1-) 2-imidazolidinone-1-yl (ethyl (4-pipidale (-H1-indole)) - Google Patents
A non-typical neuroleptic preparation that includes 5-chloro-1-) 4-fluorophenyl (-3-) 1-) 2-imidazolidinone-1-yl (ethyl (4-pipidale (-H1-indole))Info
- Publication number
- IL94021A IL94021A IL9402190A IL9402190A IL94021A IL 94021 A IL94021 A IL 94021A IL 9402190 A IL9402190 A IL 9402190A IL 9402190 A IL9402190 A IL 9402190A IL 94021 A IL94021 A IL 94021A
- Authority
- IL
- Israel
- Prior art keywords
- indole
- ethyl
- chloro
- imidazolidinon
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB898908085A GB8908085D0 (en) | 1989-04-11 | 1989-04-11 | New therapeutic use |
Publications (2)
Publication Number | Publication Date |
---|---|
IL94021A0 IL94021A0 (ko) | 1991-01-31 |
IL94021A true IL94021A (en) | 1994-01-25 |
Family
ID=10654774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL9402190A IL94021A (en) | 1989-04-11 | 1990-04-05 | A non-typical neuroleptic preparation that includes 5-chloro-1-) 4-fluorophenyl (-3-) 1-) 2-imidazolidinone-1-yl (ethyl (4-pipidale (-H1-indole)) |
Country Status (18)
Country | Link |
---|---|
US (1) | US5112838A (ko) |
EP (1) | EP0392959B1 (ko) |
JP (1) | JP2775191B2 (ko) |
KR (1) | KR920008703B1 (ko) |
AT (1) | ATE157005T1 (ko) |
AU (1) | AU621735B2 (ko) |
CA (1) | CA2014208C (ko) |
CY (1) | CY2082B1 (ko) |
DE (2) | DE19875011I2 (ko) |
DK (1) | DK0392959T3 (ko) |
GB (1) | GB8908085D0 (ko) |
HK (1) | HK1002825A1 (ko) |
IE (1) | IE81157B1 (ko) |
IL (1) | IL94021A (ko) |
NL (1) | NL980008I1 (ko) |
NZ (2) | NZ243765A (ko) |
SG (1) | SG48234A1 (ko) |
ZA (1) | ZA902785B (ko) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5238945A (en) * | 1989-04-11 | 1993-08-24 | H. Lundbeck A/S | Method of treating psychoses |
DK238190D0 (da) * | 1990-10-03 | 1990-10-03 | Lundbeck & Co As H | Depotderivater |
US5643784A (en) * | 1990-12-04 | 1997-07-01 | H, Lundbeck A/S | Indan derivatives |
NZ243065A (en) * | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
DK206591D0 (da) * | 1991-12-23 | 1991-12-23 | Lundbeck & Co As H | Behandling af psykoser |
DK8492D0 (da) * | 1992-01-23 | 1992-01-23 | Lundbeck & Co As H | Behandling af psykoser |
DK123493D0 (da) * | 1993-11-01 | 1993-11-01 | Lundbeck & Co As H | Compounds |
JP2000507544A (ja) | 1996-03-25 | 2000-06-20 | イーライ・リリー・アンド・カンパニー | 痛みの治療方法 |
ZA973433B (en) * | 1996-04-24 | 1997-12-10 | Shionogi & Co | A sertindole-containing preparation and a method for producing the same. |
AU745641B2 (en) * | 1997-10-27 | 2002-03-28 | Cortex Pharmaceuticals, Inc. | Treatment of schizophrenia with ampakines and neuroleptics |
GB9805716D0 (en) * | 1998-03-17 | 1998-05-13 | Merck Sharp & Dohme | Therapeutic agents |
US6489341B1 (en) | 1999-06-02 | 2002-12-03 | Sepracor Inc. | Methods for the treatment of neuroleptic and related disorders using sertindole derivatives |
FR2802101B1 (fr) | 1999-12-10 | 2003-02-28 | Aventis Pharma Sa | Association de cymemazine et d'un neuroleptique atypique |
US20040023951A1 (en) * | 2001-06-18 | 2004-02-05 | Bymaster Franklin Porter | Combination therapy for treatment of psychoses |
ATE503845T1 (de) * | 2001-12-10 | 2011-04-15 | Novartis Pharma Gmbh | Verfahren zur behandlung von psychosen und schizophrenie auf der basis eines polymorphismus im cntf gen |
MXPA04009365A (es) * | 2002-03-27 | 2005-01-25 | Lundbeck & Co As H | Metodo para la manufactura de sertindol. |
AU2004237951A1 (en) * | 2003-05-16 | 2004-11-25 | Pfizer Products Inc. | Therapeutic combinations of atypical antipsychotics with GABA modulators, anticonvulsants or benzodiazapines |
GB0326148D0 (en) | 2003-11-10 | 2003-12-17 | Lilly Co Eli | Morpholine derivatives |
WO2005102366A2 (en) * | 2004-04-19 | 2005-11-03 | Philip Maxwell Satow | Lithium combinations, and uses related thereto |
CA2565996A1 (en) * | 2004-05-11 | 2005-11-17 | Pfizer Products Inc. | Combination of atypical antipsychotics and 5-ht1b receptor antagonists |
MY147767A (en) * | 2004-06-16 | 2013-01-31 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
TW200612905A (en) * | 2004-06-16 | 2006-05-01 | Janssen Pharmaceutica Nv | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
TW200616608A (en) * | 2004-07-09 | 2006-06-01 | Forest Laboratories | Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients |
BRPI0514278A (pt) * | 2004-08-24 | 2008-06-10 | Janssen Pharmaceutica Nv | derivados de sulfamida de heteroarila benzo-fundida úteis como agentes anti-convulsivante |
AU2006249577A1 (en) * | 2005-05-20 | 2006-11-30 | Janssen Pharmaceutica N.V. | Process for preparation of sulfamide derivatives |
US20070212412A1 (en) * | 2005-09-08 | 2007-09-13 | H. Lundbeck A/S | Stable solid formulation of sertindole |
US8497298B2 (en) * | 2005-12-19 | 2013-07-30 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels |
US8691867B2 (en) * | 2005-12-19 | 2014-04-08 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction |
US8937096B2 (en) | 2005-12-19 | 2015-01-20 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder |
US20070155823A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents |
US8716231B2 (en) | 2005-12-19 | 2014-05-06 | Janssen Pharmaceutica Nv | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain |
US8492431B2 (en) * | 2005-12-19 | 2013-07-23 | Janssen Pharmaceutica, N.V. | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity |
US20070155827A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression |
US20070155824A1 (en) * | 2005-12-19 | 2007-07-05 | Smith-Swintosky Virginia L | Use of benzo-fused heterocycle sulfamide derivatives for disease modification / epileptogenesis |
US20070191451A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of benzo-heteroaryl sulfamide derivatives as neuroprotective agents |
US20070191460A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Disease Modification / Epileptogenesis |
US20070191474A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine |
US20070191450A1 (en) * | 2006-02-15 | 2007-08-16 | Smith-Swintosky Virginia L | Use of Benzo-Heteroaryl Sulfamide Derivatives for the Treatment of Mania and Bipolar Disorder |
TW200812573A (en) * | 2006-05-19 | 2008-03-16 | Janssen Pharmaceutica Nv | Co-therapy for the treatment of epilepsy and related disorders |
TW200821296A (en) * | 2006-06-01 | 2008-05-16 | Lundbeck & Co As H | Use of sertindole for the preventive treatment of suicidal behaviour |
ATE523602T1 (de) | 2006-06-12 | 2011-09-15 | Hadasit Med Res Service | Mit durch antipsychotika induzierten extrapyramidalen symptomen assoziierte rgs2- genotypen |
EP2578216A1 (en) | 2006-11-22 | 2013-04-10 | Seaside Therapeutics, Inc. | Methods of treating fragile x syndrome |
WO2008106144A2 (en) * | 2007-02-28 | 2008-09-04 | Nupathe Inc. | Implants for the treatment of psychiatric states |
US20090247617A1 (en) * | 2008-03-26 | 2009-10-01 | Abdel-Magid Ahmed F | Process for the preparation of benzo-fused heteroaryl sulfamates |
WO2009128058A1 (en) | 2008-04-18 | 2009-10-22 | UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al | Psycho-pharmaceuticals |
BRPI0915890A2 (pt) | 2008-06-23 | 2015-11-03 | Janssen Pharmaceutica Nv | forma cristalina de (2s)-(-)-n-(6-cloro-2,3-di-hidro-benzo[1,4]dioxin-2-ilmetil)-sulfamida |
EP2321011A1 (en) * | 2008-06-25 | 2011-05-18 | Pfizer Inc. | Diaryl compounds and uses thereof |
US8815939B2 (en) | 2008-07-22 | 2014-08-26 | Janssen Pharmaceutica Nv | Substituted sulfamide derivatives |
US8252801B1 (en) | 2009-06-03 | 2012-08-28 | Abbott Laboratories | Treatment of schizophrenia and related disorders |
WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4359468A (en) * | 1981-02-25 | 1982-11-16 | Boehringer Ingelheim Ltd. | Antiallergic N-[4-(indolyl)-piperidino-alkyl]-benzimidazolones |
IE58370B1 (en) * | 1985-04-10 | 1993-09-08 | Lundbeck & Co As H | Indole derivatives |
US4742057A (en) * | 1985-12-05 | 1988-05-03 | Fujisawa Pharmaceutical Co., Ltd. | Antiallergic thiazole compounds |
ZA891901B (en) * | 1988-03-17 | 1989-11-29 | Merrell Dow Pharma | Method for the treatment of the extrapyramidal side effects associated with neuroleptic therapy |
-
1989
- 1989-04-11 GB GB898908085A patent/GB8908085D0/en active Pending
-
1990
- 1990-03-21 IE IE105190A patent/IE81157B1/en not_active IP Right Cessation
- 1990-03-30 EP EP90610022A patent/EP0392959B1/en not_active Expired - Lifetime
- 1990-03-30 SG SG1996008153A patent/SG48234A1/en unknown
- 1990-03-30 DE DE1998175011 patent/DE19875011I2/de active Active
- 1990-03-30 DK DK90610022T patent/DK0392959T3/da active
- 1990-03-30 AT AT90610022T patent/ATE157005T1/de active
- 1990-03-30 DE DE69031290T patent/DE69031290T2/de not_active Expired - Lifetime
- 1990-04-03 NZ NZ243765A patent/NZ243765A/en unknown
- 1990-04-03 NZ NZ233179A patent/NZ233179A/en unknown
- 1990-04-05 IL IL9402190A patent/IL94021A/en active Protection Beyond IP Right Term
- 1990-04-06 JP JP2090502A patent/JP2775191B2/ja not_active Expired - Lifetime
- 1990-04-09 CA CA002014208A patent/CA2014208C/en not_active Expired - Lifetime
- 1990-04-10 AU AU53037/90A patent/AU621735B2/en not_active Expired
- 1990-04-11 KR KR1019900004984A patent/KR920008703B1/ko not_active IP Right Cessation
- 1990-04-11 US US07/508,240 patent/US5112838A/en not_active Expired - Lifetime
- 1990-04-11 ZA ZA902785A patent/ZA902785B/xx unknown
-
1998
- 1998-02-18 NL NL980008C patent/NL980008I1/nl unknown
- 1998-02-19 HK HK98101302A patent/HK1002825A1/xx not_active IP Right Cessation
- 1998-10-16 CY CY9802082A patent/CY2082B1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
NL980008I1 (nl) | 1998-05-06 |
CY2082B1 (en) | 1998-10-16 |
KR920008703B1 (ko) | 1992-10-08 |
NZ233179A (en) | 1996-12-20 |
EP0392959A2 (en) | 1990-10-17 |
US5112838A (en) | 1992-05-12 |
AU5303790A (en) | 1990-10-18 |
DE69031290D1 (de) | 1997-09-25 |
GB8908085D0 (en) | 1989-05-24 |
EP0392959A3 (en) | 1992-05-06 |
AU621735B2 (en) | 1992-03-19 |
KR900015730A (ko) | 1990-11-10 |
IL94021A0 (ko) | 1991-01-31 |
IE81157B1 (en) | 2000-05-03 |
DE69031290T2 (de) | 1998-01-02 |
ZA902785B (en) | 1991-06-26 |
EP0392959B1 (en) | 1997-08-20 |
CA2014208C (en) | 1996-03-19 |
ATE157005T1 (de) | 1997-09-15 |
JPH02290872A (ja) | 1990-11-30 |
DK0392959T3 (da) | 1999-03-29 |
DE19875011I2 (de) | 2004-07-01 |
NZ243765A (en) | 1997-09-22 |
HK1002825A1 (en) | 1998-09-18 |
IE901051L (en) | 1990-10-11 |
CA2014208A1 (en) | 1990-10-11 |
SG48234A1 (en) | 1998-04-17 |
JP2775191B2 (ja) | 1998-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5112838A (en) | Method of treating psychoses in human beings with the atypical neuroleptic 5-chloro-1-(4-fluorophenyl)-3-(1-(2-(2-imidazolidinon-1-yl)ethyl-4-piperidyl)1h-indole | |
US5238945A (en) | Method of treating psychoses | |
DE69918404T2 (de) | Aminophenoxyessigsäure derivate als neuroschützende mittel | |
US6169105B1 (en) | Potentiation of drug response | |
US6114356A (en) | Method for treating gastrointestinal disorders using (+) norcisapride | |
US6548082B1 (en) | Methods for treating apnea and apnea disorders using optically pure R(+) ondansetron | |
US6632827B2 (en) | Compositions of optically pure (+) norcisapride | |
SK15472001A3 (sk) | Použitie saredutantu a jeho farmaceuticky prijateľných solí na prípravu liečiva použiteľného na liečenie alebo prevenciu porúch nálady, porúch adaptácie alebo stavov úzkosti a depresie | |
AU668537B2 (en) | Use of arylindole derivatives for the treatment of psychoses | |
WO1993014758A1 (en) | Use of 3-arylindole and 3-arylindazole derivatives for the treatment of psychoses | |
GB2362826A (en) | A pharmaceutical composition comprising a serotonin transport inhibitor and a serotonin recptor antagonist | |
US20030212109A1 (en) | Pharmaceutical compositions and their use | |
EP1435238A1 (en) | Methods for treating apnea and apnea disorders using optically pure R (+) ondansetron |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
KB | Patent renewed | ||
KB | Patent renewed | ||
KB | Patent renewed | ||
EXTF | Application for patent extension filed | ||
KB | Patent renewed | ||
EXTG | Extension of patent term granted |
Extension date: 20100523 |
|
EXTG | Extension of patent term granted |